Interní Med. 2009; 11(9): 390-394

Macrovascular complications in diabetes mellitus

MUDr. Vladimíra Fejfarová Ph.D
Centrum diabetologie IKEM, Praha

Diabetes mellitus often leads to an acceleration of atherosclerosis via a range of pathophysiological mechanisms. In diabetes mellitus

macrovascular complications such as coronary artery disease, peripheral arterial disease and ischemic strokes could develop based on

atherosclerotic process. Their occurrences could be partially influenced by preventive precautions including adjustment of lifestyle and

treatment of risk factors.

Keywords: diabetes mellitus, macrovascular complications, atherosclerosis, endothelial dysfunctions.

Published: October 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fejfarová V. Macrovascular complications in diabetes mellitus. Interní Med. 2009;11(9):390-394.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bartoš V, Pelikánová T, et al. Praktická diabetologie, 2. vydání, Praha: Jessenius Maxdorf 2000.
    2. Janíčková Žďárská D. Diabetes mellitus ve vztahu ke kardiovaskulárním chorobám. Interní medicína pro praxi 2005; 7-8: 332-335.
    3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    4. Perušičová J, Šmahelová A. Chronické komplikace u diabetes mellitus (1. část). Interní medicína pro praxi 2001; 1: 34-38.
    5. Murín J. Akútny koronárny syndrom a nešpecificky aterosklerotický zápal. Interní medicína pro praxi 2003; 1: 24-26.
    6. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007; 67 (7): 997-1026. Go to original source... Go to PubMed...
    7. Perušičová J. Trendy soudobé diabetologie, Praha: Galén 1999.
    8. Porush JG, Faubert PF. Clinician´s Manual on Hypertension, Diabetes mellitus and Nephropathy. London: Science Press Ltd. 2001: 1-5.
    9. Malmberg K. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515. Go to original source... Go to PubMed...
    10. Li JY, Sun S, Wu SJ. Continuous insulin infusion improves postoperative glucose kontrol in patients with diabetes mellitus undergoing coronary Artury bypass surgery. Tex Heart Indy J 2006; 33(4): 445-451.
    11. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and Acute Coronary Syndrome. A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism, Anesthesiology 2008; 109: 14-24. Go to original source... Go to PubMed...
    12. Lavi S, Kapeliovich M, Gruberg L, et al. Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: impact on long-term prognosis. Int J Cardiol 2008; 123(2): 117-122. Go to original source... Go to PubMed...
    13. Madonna R, Colella ME, De Caterina R. Glycemic kontrol in the coronary care unit: prognostic value and new therapeutic strategie. G Ital Cardiol 2008; 9(9): 603-614. Go to PubMed...
    14. Cola C, Sabaté M. Revascularization in high risk patients: diabetes mellitus. Minerva Cardioangiol 2007; 55 (5): 557-577. Go to PubMed...
    15. Fejfarová V, Jirkovská A, Skibová J, Petrov V. The association of resistant Staphylococcus aureus and the rate of lower limb amputations in patients with the diabetic foot. Diabetologia 2006; (Suppl. 1): 685-686.
    16. Jirkovská A, et al. Syndrom diabetické nohy, Praha: Jessenius Maxdorf 2006.
    17. Dahlof B, Devereux RB, Kjedsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    18. Škoda O. Antiagregační léčba po ischemické cévní mozkové příhodě. Interní Med 2006; 12: 534-538.
    19. Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2009; 32(1): 193-203. Go to original source... Go to PubMed...
    20. Radermecker RP, Philips JC, Jandrain B, Paquot N, Scheen AJ: Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev Med Liege 2008; 63(7-8): 511-518. Go to PubMed...
    21. Cugnet-Anceau C, Bauduceau B. Glycemic control and cardiovascular morbimortality: What´s new with the 2008 studies? Ann Endocrinol (Paris) 2009; 4.
    22. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.